Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.
ASCO 2020: Update on Genitourinary Cancers
Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer.
Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.
Neeraj Agarwal, MD, discusses the COSMIC-021 trial, the findings from cohort 6 in metastatic castration-resistant prostate cancer, and the planned phase 3 trial that will evaluate the combination on a larger scale.
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5